| Literature DB >> 33404977 |
Sharifa Hasana1, Md Farhad Hossain2,3, Maroua Jalouli4, Md Tanvir Kabir5, Md Giash Uddin6, Mir Imam Ibne Wahed7, Tapan Behl8, May N Bin-Jumah9, Mohamed M Abdel-Daim10,11, Lotfi Aleya12, Md Sahab Uddin13,14.
Abstract
The new coronavirus (CoV), called novel coronavirus disease 2019 (COVID-19), belongs to the Coronaviridae family which was originated from the sea market in Wuhan city in China, at the end of the year 2019. COVID-19 and severe acute respiratory syndrome (SARS) are belonging to the same family (Coronaviridae). The current outbreak of COVID-19 creates public concern and threats all over the world and now it spreads out to more than 250 countries and territories. The researchers and scientists from all over the world are trying to find out the therapeutic strategies to abate the morbidity and mortality rate of the COVID-19 pandemic. The replication, spreading, and severity of SARS-CoV2 depend on environmental settings. Noteworthy, meteorological parameters are considered as crucial factors that affect respiratory infectious disorders, although the controversial effect of the meteorological parameter is exposed against COVID-19. Besides, COVID-19 accelerates the pathogenesis of the neurological disorders. However, the pathogenic mechanisms between COVID-19 and neurological disorders are still unclear. Hence, this review is focused on the genomics and ecology of SARS-CoV2 and elucidated the effects of climatic factors on the progression of COVID-19. This review also critically finds out the vulnerability between COVID-19 and neurological disorders based on the latest research data.Entities:
Keywords: COVID-19; Climatic factors; Genetic diversity; Neurological disorders; SARS-CoV2
Mesh:
Year: 2021 PMID: 33404977 PMCID: PMC7786338 DOI: 10.1007/s12035-020-02239-z
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590
Number of COVID-19 cases and deaths reported weekly by WHO region, and global deaths (as of 18 October 2020) [21]
| Regions | New cases in last 7 days (%) | Cumulative cases (%) | New deaths in last 7 days (%) | Cumulative deaths (%) | Mortality last 7 days (%) | Total mortality (%) |
|---|---|---|---|---|---|---|
| Europe | 927,433 (38%) | 8,027,954 (20%) | 8386 (23%) | 256,540 (23%) | 0.90 | 3.20 |
| Americas | 798,794 (33%) | 18,800,094 (47%) | 16,283 (45%) | 608,727 (55%) | 2.04 | 3.24 |
| South-East Asia | 513,444 (21%) | 8,546,666 (21%) | 6864 (19%) | 135,275 (12%) | 1.34 | 1.58 |
| Eastern Mediterranean | 144,133 (6%) | 2,786,477 (7%) | 3492 (10%) | 70,902 (6%) | 2.42 | 2.54 |
| Africa | 31,473 (1%) | 1,267,664 (3%) | 1058 (3%) | 28,469 (3%) | 3.36 | 2.25 |
| Western Pacific | 28,317 (1%) | 688,737 (2%) | 464 (1%) | 14,823 (1%) | 1.64 | 2.15 |
| Others | - | 741 (< 1%) | - | 13 (< 1%) | - | 1.75 |
| Globally | 2,443,594 (100%) | 40,118,333 (100%) | 36,547 (100%) | 1,114,74 (100%) | 1.64 | 2.78 |
Fig. 1Schematic diagram of SARS-COV2 and COVID-19 genome arrangement. A. The comparison between genomic and open-reading frames (ORFs) is mentioned. The full length of the genome sequence is ~ 30 kb. B. Viral RNA is associated with nucleocapsid (N) protein. Spikes (S), envelope (E) as well as membrane (M) are embedded in a lipid bilayer
Fig. 2Used PPE in the land site and ocean spreads COVID-19 transmission. Lower temperature and higher humidity are associated with COVID spreading. Besides, the transmission of COVID-19 might be increased though spreading droplets or touching contaminated place
Fig. 3Neurological disorders triggered by SARS-CoV2. At first, SARS-CoV2 enters into the host cell and releases viral RNA which, in turn, aggregates proteins into CD4+ T cells. CD4+ T cells active microglia and produce elevated level of pro-inflammatory markers and these markers accelerate mitochondrial dysfunction and neuronal death resulting in progression of neurological disorders. BBB, blood–brain barrier; CNS, central nervous system